Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study Nanoscience Investing
Nano One Provides Q2 2022 Corporate Update On Commercialisation Strategy and Expansion Plans Technology Investing
Nano One Successfully Completes Phase One of its Co-Development Agreement with Niobium Producer CBMM Technology Investing
